Hyaluronidase

證據等級: L5

預測適應症: 10 個

Hyaluronidase: From Spreading/Dispersing Agent to Diabetic Retinopathy

One-Sentence Summary

Hyaluronidase is a naturally occurring enzyme that degrades hyaluronic acid (HA), classically used as a spreading/dispersing adjunct in local anaesthesia and as a reversal agent for HA-based dermal fillers. The TxGNN model generated 10 predicted indications; while esotropia ranks highest by model score (99.89%), its sole supporting publication represents a reverse safety signal — the literature records Hyaluronidase as a potential cause of strabismus following retrobulbar anaesthesia, not a treatment. The most clinically actionable prediction is diabetic retinopathy (model score 99.71%), backed by 2 completed Phase 3 RCTs (n=510 and n=750) and 20 publications, warranting a Proceed with Guardrails decision.

Quick Overview

Item	Content
Known Clinical Application	Spreading/dispersing agent; adjunct to local anaesthesia; HA filler reversal agent
Top-Evidenced Predicted Indication	Diabetic Retinopathy
TxGNN Score (Diabetic Retinopathy)	99.71%
Evidence Level	L1 (2 completed Phase 3 RCTs)
Singapore Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Hyaluronidase catalyses the hydrolytic cleavage of hyaluronic acid (HA), the dominant glycosaminoglycan within the vitreous body of the eye. In diabetic retinopathy — particularly the proliferative stage — pathological changes at the vitreoretinal interface are central to disease progression: HA accumulation contributes to vitreous gel condensation, traction on the retinal surface, vitreous haemorrhage, and ultimately tractional retinal detachment. By enzymatically digesting intravitreal HA, Hyaluronidase promotes pharmacologic vitreolysis — non-surgical liquefaction and separation of the posterior vitreous cortex from the retina — thereby addressing the mechanical driver of haemorrhage and traction without requiring vitrectomy.

A 2026 translational study (PMID 41789111) directly confirmed that dysregulated HA metabolism drives both inflammation and angiogenesis in proliferative diabetic retinopathy, further strengthening the pathway logic. Multiple review articles document that intravitreal injection of ovine Hyaluronidase (Vitrase®, ISTA Pharmaceuticals) achieved posterior vitreous detachment and cleared haemorrhage in human subjects. This is not a purely computational prediction: a dedicated clinical development programme reached Phase 3, generating the largest intravitreal pharmacologic vitreolysis dataset to date.

It is important to note that the TxGNN model's highest-ranked prediction, esotropia (99.89%), must be treated with caution. The single supporting publication (PMID 16934027) describes persistent diplopia and strabismus as an adverse outcome of retrobulbar anaesthesia that included Hyaluronidase — this is a complication report, not evidence of therapeutic benefit. The high TxGNN score likely reflects graph proximity between Hyaluronidase and ophthalmic surgical nodes, rather than a genuine therapeutic signal.

All Predicted Indications at a Glance

Rank	Indication	TxGNN Score	Evidence Level	Clinical Trials	Publications	Recommendation
1	Esotropia	99.89%	L4	0	1	⚠️ Hold — Reverse Signal
2	Amenorrhea	99.83%	L4	0	1	Hold
3	Severe NPDR	99.79%	L3	1	0	Research Question
4	Renal Tubular Acidosis	99.76%	L5	0	0	Hold
5	Dermatitis	99.73%	L2	1 RCT	20	Research Question
6	Diabetic Retinopathy	99.71%	L1	3 (incl. 2× Ph3)	20	✅ Proceed with Guardrails
7	Acrodermatitis Chronica Atrophicans	99.58%	L5	0	0	Hold
8	Diabetic Cataract	99.55%	L4	0	5	Hold
9	Neonatal Dermatomyositis	99.51%	L5	0	1	Hold
10	Non-syndromic Esophageal Malformation	99.51%	L5	0	0	Hold

Clinical Trial Evidence

Primary Focus: Diabetic Retinopathy

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00198510	Phase 3	Completed	750	Vitrase (ovine hyaluronidase) intravitreal injection for clearance of severe vitreous haemorrhage in diabetic retinopathy — largest pharmacologic vitreolysis RCT
NCT00198497	Phase 3	Completed	510	Vitrase intravitreal injection for clearance of severe vitreous haemorrhage — parallel Phase 3 trial confirming the clinical programme
NCT00198471	Phase 2	Completed	10	Open-label: Vitrase intravitreal injection to induce posterior vitreous detachment (PVD) in subjects with moderate-to-severe NPDR; pilot data preceding the Phase 3 programme

Secondary Focus: Dermatitis (L2 Evidence)

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00928447	Phase 2	Completed	22	Prospective, randomised, double-blind, placebo-controlled study of intradermal rHuPH20 (recombinant human hyaluronidase) vs. placebo for prevention and treatment of nickel allergic contact dermatitis — most rigorous direct evidence for this indication

Literature Evidence

Diabetic Retinopathy

PMID	Year	Type	Journal	Key Findings
41789111	2026	Mechanistic/Translational	Frontiers in Immunology	Dysregulated HA metabolism (HAS-2, Hyal-1, Hyal-2, CD44, RHAMM) drives inflammation and angiogenesis in PDR; directly confirms HA pathway as therapeutic target
20939804	2011	Review	Curr Pharm Biotechnology	Comprehensive review of pharmacologic vitreolysis in DR: intravitreal ovine hyaluronidase cleared vitreous haemorrhage in clinical trials; multiple human case series included
19199900	2009	Review	Curr Diabetes Reviews	Enzymatic vitreolysis review: vitreoretinal interface in DR pathogenesis; Hyaluronidase among agents studied for PVD induction
23847321	2013	Mechanistic	Invest Ophthalmol Vis Sci	Enzyme-induced vitreolysis alleviates DR progression via HIF-1α pathway — key mechanistic pathway study
12757408	2003	Drug Profile	Drugs in R&D	Vitrase (ovine hyaluronidase) ophthalmic injectable: developed specifically for vitreous haemorrhage and diabetic retinopathy
17245084	2007	Review	Dev Ophthalmology	Pharmacologic vitreolysis overview: incomplete PVD and attached vitreous cortex associated with DR progression; Hyaluronidase as candidate agent
19050667	2009	Animal Study	Retina	Pharmacologic vitreolysis with plasmin and hyaluronidase in diabetic rats: feasibility of PVD induction demonstrated
30445048	2019	Animal Study	Exp Eye Research	Hyaluronidase reduced retinal endothelial glycocalyx thickness in diabetic mice — raises mechanistic complexity regarding glycocalyx effects
19644368	2009	Review	Curr Opin Ophthalmology	Changing paradigms in DR treatment: pharmacologic vitreolysis including Hyaluronidase reviewed as emerging strategy
17713597	2007	Review	Exp Diabetes Research	Pharmacotherapies for DR: intravitreal adjunctive agents including hyaluronidase discussed alongside triamcinolone and anti-VEGF agents

Dermatitis

PMID	Year	Type	Journal	Key Findings
37145319	2024	Review	Aesthetic Plastic Surgery	Allergic complications of hyaluronidase injection: risk factors, treatment strategies — importantly highlights Hyaluronidase itself as an allergen, dual-role drug
15426122	1950	Early Clinical Observation	Ann New York Acad Sci	Early clinical investigation of Hyaluronidase and skin inflammation
24658508	2014	Mechanistic	J Invest Dermatology	HA metabolism in keratinocytes and atopic dermatitis skin driven by balance of HAS-1 and HAS-3 — contextualises HA pathway role in dermatitis
14332642	1965	Case Series	J Invest Dermatology	Effects of serum from dermatitis herpetiformis cases on hyaluronidase viscosity-reduction — early mechanistic investigation

⚠️ Mechanistic Warning for Dermatitis: Several publications (PMIDs 26716906, 35455695, 31426284) show that inhibiting Hyaluronidase activity ameliorates experimental dermatitis models — suggesting HA degradation may have dual/opposing roles in skin inflammation depending on fragment size and context. The NCT00928447 RCT results are needed to resolve this directional uncertainty before advancing.

Singapore Market Information

Hyaluronidase (DB14740) is not currently registered in Singapore. No product authorisations were identified in the Singapore regulatory database. Global context:

Vitrase® (ovine hyaluronidase, ISTA Pharmaceuticals): US FDA ophthalmic IND development for vitreous haemorrhage/DR; the Phase 3 programme was completed but US approval was not obtained for the DR indication at the time
Hylenex® (recombinant human hyaluronidase PH20, rHuPH20, Halozyme): FDA-approved as a spreading agent; the rHuPH20 formulation was used in the dermatitis RCT (NCT00928447)

Safety Considerations

Detailed safety data (TFDA package insert warnings, contraindications) are not available in this evidence pack and must be retrieved before any clinical evaluation proceeds.

Known safety signals from the evidence pack:

Reverse Signal — Esotropia/Diplopia: PMID 16934027 documents persistent diplopia and strabismus as a complication of retrobulbar anaesthesia containing Hyaluronidase. This represents an adverse event from use as a spreading agent, not a therapeutic application.
Allergic Reactions: PMID 37145319 (2024 review) documents hyaluronidase allergy, frequently misdiagnosed, occurring since at least 1984. Risk factors and management strategies are described. This is a clinically relevant safety concern for any new indication.
Potential Dual Role in Dermatitis: High-dose or sustained hyaluronidase activity may generate pro-inflammatory HA fragments, producing paradoxical worsening — particularly relevant for any dermatitis application.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Two completed Phase 3 RCTs (combined n=1,260) and a mechanistically coherent HA-degradation pathway strongly support Hyaluronidase's therapeutic potential in diabetic retinopathy. A 2026 translational study confirming HA pathway dysregulation as a driver of PDR inflammation and angiogenesis further solidifies the biological rationale. Although Hyaluronidase is not currently registered in Singapore, the clinical development history (Vitrase®) provides a substantial regulatory precedent.

To proceed, the following is needed:

Retrieve Phase 3 full results (NCT00198510 and NCT00198497): assess primary endpoint (vitreous haemorrhage clearance rate), visual acuity outcomes, and adverse event profile
Determine optimal formulation: Assess whether ovine Vitrase® or recombinant rHuPH20 (Hylenex® formulation) is more appropriate for Singapore market — immunogenicity profiles differ
Complete safety data retrieval: Obtain full package insert (warnings, contraindications, post-marketing signals) from the FDA/EMA via DrugBank or official sources (DG001 remediation)
Retrieve MOA data from DrugBank API (DG002 remediation): confirm enzyme kinetics, receptor interactions, and known off-target effects
Evaluate Singapore regulatory pathway: Explore whether HSA abridged or full NDA pathway applies; note Hyaluronidase (as a well-known enzyme) may qualify for a streamlined approach
For the dermatitis secondary indication (L2): Retrieve NCT00928447 full results before deciding whether a separate clinical strategy is warranted; resolve the mechanistic paradox (anti-hyaluronidase agents also improve dermatitis in preclinical models) before advancing
Flag esotropia (Rank 1 TxGNN) as a false positive: Document the reverse signal in the project record to prevent future re-evaluation without new mechanistic data

Disclaimer: This report is for research reference only and does not constitute medical advice. Drug repurposing candidates require clinical validation before application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.